Ann: Review of drill-hole FW220009 at the Mount Lamb NE prospect, page-207

First 207 Last

Share
Profile

Follow
allens

3,826 Posts.

1550

24/07/22

13:30

Post #: 62697337
Share
Originally posted by christs23 ↑

Having re-read the recent announcements, my conclusions are as follows:

The geologists are excited about what they see so far. The indicators of an IOCG Tier 1 type deposit are there.

Assays will be key in determining where the 'guts' of this thing is and where the next drills should go.

Bang for Buck' is the new strategy in managing cash flow. They are confident they have something, so focus the energy and spend on the big prize, rather than diluting resources across multiple sites. Whatever is in the ground in the other tenements isn't going anywhere.

Hole 10 will be the last of Stage 1 of the drill program. It probably won't be the discovery hole, but like the other holes, the assays will build the bigger picture and help determine where a revised Stage 2 program should concentrate.

The BOD are working hard and are fully aware of the importance of having the OA's in the money and exercised before expiry.

I far prefer a methodical, analytical approach, combined with good fiscal management, which is what the new CEO appears to be doing. The current SP doesn't bother me, particularly given the below average volumes. I see it as an opportunity, rather than a reflection of the fundamentals.

As the good doctor has said many times, this is a marathon, not a sprint!

Expand

christs23.

Your post has nailed it, very well written and as I see close to the reality of present situation. Just hope Hole 10 does deliver thats all I can add.
ICG Price at posting: 6.4¢ Sentiment: Buy Disclosure: Held
10 Upvote

0 Great analysis

Reply

Top Stories

CHM

Leukaemia patient shows complete response in Chimeric Therapeutics' latest trial

RCE

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

Arika to pump $3.2M into gold exploration at WA's Yundamindra following strong maiden program

NYR

Nyrada rat study shows no genotoxicity in brain injury drug NYR-BI03

NEU

Neuren sees FDA greenlight for 3rd trial into children with Phelan-McDermid syndrome

There are more pages in this discussion • 64 more messages in this thread...

First 207 Last

Add ICG (ASX) to my watchlist

(20min delay)
Last 0.5¢		Change 0.000(0.00%)		Mkt cap ! $4.066M

Open	High	Low	Value	Volume
0.5¢	0.5¢	0.5¢	$2.25K	450K

Buyers (Bids)

No.	Vol.	Price($)
2	1850000	0.5¢

Sellers (Offers)

Price($)	Vol.	No.
0.6¢	1277593	6

View Market Depth

No.	Vol.	Price($)
2	1850000	0.005
7	6929194	0.004
13	18176780	0.003
4	4399980	0.002
4	7199950	0.001

Price($)	Vol.	No.
0.006	1277593	6
0.007	924600	3
0.008	1201540	5
0.009	1033282	3
0.010	1000000	1

Last trade - 14.22pm 07/10/2024 (20 minute delay)

ICG (ASX) Chart

Ann: Review of drill-hole FW220009 at the Mount Lamb NE prospect, page-207

Leukaemia patient shows complete response in Chimeric Therapeutics' latest trial

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

Arika to pump $3.2M into gold exploration at WA's Yundamindra following strong maiden program

Nyrada rat study shows no genotoxicity in brain injury drug NYR-BI03

Neuren sees FDA greenlight for 3rd trial into children with Phelan-McDermid syndrome

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

Ann: Review of drill-hole FW220009 at the Mount Lamb NE prospect, page-207

Top Stories

Leukaemia patient shows complete response in Chimeric Therapeutics' latest trial

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

Arika to pump $3.2M into gold exploration at WA's Yundamindra following strong maiden program

Nyrada rat study shows no genotoxicity in brain injury drug NYR-BI03

Neuren sees FDA greenlight for 3rd trial into children with Phelan-McDermid syndrome

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News